Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

Leukemia - 1 May 2007

Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides
Share to Imatinib Mesylate
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Polycythemia

Share to Pyrimidines

Source

Identifiers

PMID: 17301812
DOI: 10.1038/sj.leu.2404591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.PMID 17301812Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.Semantic proximity Read ↗

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.Semantic proximity Read ↗

JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.Semantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.